A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Tolerability of Gabapentin Enacarbil in Subjects with Restless Legs Syndrome

Overview

Journal J Clin Sleep Med

Specialties Neurology
Psychiatry

Date 2011 Jun 17

PMID 21677899

Citations 39

Authors

Daniel O Lee

Ronald B Ziman

A Thomas Perkins

J Steven Poceta

Arthur S Walters

Ronald W Barrett

Affiliations

Soon will be listed here.

Abstract

Study Objective: To evaluate the efficacy and tolerability of gabapentin enacarbil (GEn) 1200 mg or 600 mg compared with placebo in subjects with moderate-to-severe primary restless legs syndrome (RLS).

Methods: This 12-week, multicenter, double-blind, placebo-controlled study randomized subjects (1:1:1) to GEn 1200 mg, 600 mg, or placebo. Co-primary endpoints: mean change from baseline in International Restless Legs Scale (IRLS) total score and proportion of responders (rated as "very much" or "much" improved) on the investigator-rated Clinical Global Impression-Improvement scale (CGI-I) at Week 12 LOCF for GEn 1200 mg compared with placebo. Secondary endpoints included GEn 600 mg compared with placebo on the IRLS and CGI-I at Week 12 LOCF and subjective measures for sleep. Safety and tolerability assessments included adverse events.

Results: 325 subjects were randomized (GEn 1200 mg = 113; 600 mg = 115; placebo = 97). GEn 1200 mg significantly improved mean [SD] IRLS total score at Week 12 LOCF (baseline: 23.2 [5.32]; Week 12: 10.2 [8.03]) compared with placebo (baseline: 23.8 [4.58]; Week 12: 14.0 [7.87]; adjusted mean treatment difference [AMTD]: -3.5; p = 0.0015), and significantly more GEn 1200 mg-treated (77.5%) than placebo-treated (44.8%) subjects were CGI-I responders (p < 0.0001). Similar significant results were observed with GEn 600 mg for IRLS (AMTD: -4.3; p < 0.0001) and CGI-I (72.8% compared with 44.8%; p < 0.0001). GEn also significantly improved sleep outcomes (Post-Sleep Questionnaire, Pittsburgh Sleep Diary and Medical Outcomes Sleep Scale) compared with placebo. The most commonly reported adverse events were somnolence (GEn 1200 mg = 18.0%; 600 mg = 21.7%; placebo = 2.1%) and dizziness (GEn 1200 mg = 24.3%; 600 mg = 10.4%; placebo = 5.2%). Dizziness increased with increased dose and led to discontinuation in 2 subjects (GEn 1200 mg, n = 1; GEn 600 mg, n = 1). Somnolence led to discontinuation in 3 subjects (GEn 600 mg).

Conclusions: GEn 1200 mg and 600 mg significantly improve RLS symptoms and sleep disturbance compared with placebo and are generally well tolerated.

Citing Articles

Cole M, Simakajornboon N World J Pediatr. 2024; .

PMID: 39604768 DOI: 10.1007/s12519-024-00856-5.

Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Winkelman J, Berkowski J, DelRosso L, Koo B, Scharf M, Sharon D J Clin Sleep Med. 2024; 21(1):153-199.

PMID: 39324664 PMC: 11701280. DOI: 10.5664/jcsm.11392.

Efficacy and safety of tonic motor activation (TOMAC) for medication-refractory restless legs syndrome: a randomized clinical trial.

Bogan R, Roy A, Kram J, Ojile J, Rosenberg R, Hudson J Sleep. 2023; 46(10).

PMID: 37458698 PMC: 10566236. DOI: 10.1093/sleep/zsad190.

Effects of Gabapentin and Pregabalin on Calcium Homeostasis: Implications for Physical Rehabilitation of Musculoskeletal Tissues.

Reyes Fernandez P, Wright C, Warden S, Hum J, Farach-Carson M, Thompson W Curr Osteoporos Rep. 2022; 20(6):365-378.

PMID: 36149592 PMC: 10108402. DOI: 10.1007/s11914-022-00750-x.

Sleep Disturbance, Sleep Disorders and Co-Morbidities in the Care of the Older Person.

Mc Carthy C Med Sci (Basel). 2021; 9(2).

PMID: 34063838 PMC: 8162526. DOI: 10.3390/medsci9020031.

References

Happe S, Klosch G, Saletu B, Zeitlhofer J . Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology. 2001; 57(9):1717-9. DOI: 10.1212/wnl.57.9.1717. View

Winkelman J, Sethi K, Kushida C, Becker P, Koester J, Cappola J . Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006; 67(6):1034-9. DOI: 10.1212/01.wnl.0000231513.23919.a1. View

Monk T, Reynolds 3rd C, Kupfer D, Buysse D, Coble P, Hayes A . The Pittsburgh Sleep Diary. J Sleep Res. 1994; 3:111-20. View

Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, de Weerd A, Tidswell P . Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry. 2004; 75(1):92-7. PMC: 1757460. View

Bogan R, Fry J, Schmidt M, Carson S, Ritchie S . Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006; 81(1):17-27. DOI: 10.4065/81.1.17. View

Kushida C, Becker P, Ellenbogen A, Canafax D, Barrett R . Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009; 72(5):439-46. DOI: 10.1212/01.wnl.0000341770.91926.cc. View

Walters A, LeBrocq C, Dhar A, Hening W, Rosen R, Allen R . Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003; 4(2):121-32. DOI: 10.1016/s1389-9457(02)00258-7. View

Winkelman J, Johnston L . Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004; 5(1):9-14. DOI: 10.1016/j.sleep.2003.07.005. View

Winkelman J . A better future for patients with restless legs syndrome. Am J Med. 2007; 120(1 Suppl 1):S28-9. DOI: 10.1016/j.amjmed.2006.11.005. View

10.

Cundy K, Annamalai T, Bu L, De Vera J, Estrela J, Luo W . XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004; 311(1):324-33. DOI: 10.1124/jpet.104.067959. View

11.

Ferini-Strambi L, Aarskog D, Partinen M, Chaudhuri K, Sohr M, Verri D . Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med. 2008; 9(8):874-81. DOI: 10.1016/j.sleep.2008.09.001. View

12.

Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G . Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002; 59(10):1573-9. DOI: 10.1212/wnl.59.10.1573. View

13.

Gidal B, Radulovic L, Kruger S, Rutecki P, Pitterle M, Bockbrader H . Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000; 40(2-3):123-7. DOI: 10.1016/s0920-1211(00)00117-0. View

14.

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique. 2005; 15(1):124-9. View

15.

VOLLMER K, von Hodenberg A, Kolle E . Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung. 1986; 36(5):830-9. View

16.

Kushida C, Allen R, Atkinson M . Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med. 2004; 5(5):485-8. DOI: 10.1016/j.sleep.2004.04.004. View

17.

Kriel R, Birnbaum A, Cloyd J, Ricker B, Jones Saete C, Caruso K . Failure of absorption of gabapentin after rectal administration. Epilepsia. 1998; 38(11):1242-4. DOI: 10.1111/j.1528-1157.1997.tb01223.x. View

18.

Allen R, Picchietti D, Hening W, Trenkwalder C, Walters A, Montplaisi J . Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003; 4(2):101-19. DOI: 10.1016/s1389-9457(03)00010-8. View

19.

Allen R, Walters A, Montplaisir J, Hening W, Myers A, Bell T . Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005; 165(11):1286-92. DOI: 10.1001/archinte.165.11.1286. View

20.

Walters A, Ondo W, Dreykluft T, Grunstein R, Lee D, Sethi K . Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004; 19(12):1414-23. DOI: 10.1002/mds.20257. View